Skip to main content

Table 1 Patient characteristics in the study

From: A novel nomogram for predicting cancer-specific survival in women with uterine sarcoma: a large population-based study

Variable Training cohort Validation cohort
(n = 2702) (n = 1159)
Medium age at diagnosis, (25th–75th percentile) 62 (53–69) 60 (51–69)
Race n (%)
 White 1869 (69.2) 808 (71.2)
 Black 591 (22.1) 243 (20.2)
 Other 242 (8.6) 108 (8.6)
Marital status n (%)
 Married 1257 (47.6) 561 (48.3)
 Single 586 (22.3) 261 (22.7)
 SDW 736 (25.6) 293 (25.5)
 Unknown 123 (4.6) 44 (3.5)
Insurance record n (%)
 Yes 2584 (95.4) 1117 (96.3)
 No 118 (4.6) 42 (3.7)
Tumor size n (%)
 ≤ 50 mm 710 (23.1) 313 (23.8)
 > 50 mm 1596 (61.4) 677 (61.6)
 Unknown 396 (15.6) 169 (14.6)
Pathological grade n (%)
 I 169 (6.4) 76 (6.0)
 II 345 (12.0) 135 (11.4)
 III 1193 (43.0) 527 (44.5)
 IV 995 (38.7) 421 (38.2)
Histological type n (%)
 Sarcoma 76 (4.3) 20 (2.8)
 Leiomyosarcoma 532 (28.3) 215 (26.6)
 Adenosarcoma 124 (4.4) 45 (3.8)
 Stromal sarcoma 455 (14.1) 207 (15.5)
 Carcinosarcoma 1515 (48.8) 672 (51.3)
SEER stage n (%)
 Localized 1116 (37.4) 537 (42.5)
 Regional 825 (29.1) 321 (28.2)
 Distant 761 (33.5) 301 (29.3)
AJCC stage n (%)
 I 1225 (41.0) 573 (45.1)
 II 236 (9.7) 84 (8.1)
 III 572(20.0) 222 (20.0)
 IV 669 (29.3) 280 (26.9)
Surgery status n (%)
 Yes 2516 (90.8) 1090 (92.4)
 No/unknown 186 (9.2) 69 (7.6)
Radiotherapy status n (%)
 Yes 782 (26.3) 313 (24.6)
 No/unknown 1920 (73.7) 846 (75.4)
Chemotherapy status n (%)
 Yes 1420 (52.4) 598 (53.2)
 No/unknown 1282 (47.6) 561 (46.8)